FDA sets Sept review date for BMS’ psoriasis drug deucravacitinibThe FDA has kicked off its review of Bristol-Myers Squibb’s psoriasis therapy deucravacitinib, setting an action date of Share XFDA sets Sept review date for BMS’ psoriasis drug deucravacitinibhttps://pharmaphorum.com/news/fda-sets-sept-review-date-for-bms-psoriasis-drug-deucravacitinib/
Turkey’s home-grown COVID vaccine project nears fruitionTurkey could have its own COVID-19 vaccine Turkovac available for use by the end of the year, according Share XTurkey’s home-grown COVID vaccine project nears fruitionhttps://pharmaphorum.com/news/turkeys-home-grown-covid-vaccine-project-nears-fruition/
After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancerEli Lilly’s RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced Share XAfter Scotland says no, NICE backs Lilly’s Retsevmo for lung cancerhttps://pharmaphorum.com/news/after-scotland-says-no-nice-backs-lillys-retsevmo-for-lung-cancer/
Innovation and collaboration – the MHRA’s pandemic approachThe pandemic has propelled issues for the pharmaceutical industry to the top of the political and public agenda, Share XInnovation and collaboration – the MHRA’s pandemic approachhttps://pharmaphorum.com/market-access-2/mhra-pandemic-approach-innovation-collaboration/
FDA clears Takeda drug for post-transplant CMV infectionsTakeda has scored the first-ever FDA approval of a treatment for refractory cytomegalovirus (CMV) infections in organ transplant Share XFDA clears Takeda drug for post-transplant CMV infectionshttps://pharmaphorum.com/news/fda-clears-takeda-drug-for-post-transplant-cmv-infections/
Gilead files first hepatitis delta therapy with FDAGilead Sciences has submitted its marketing application for bulevirtide, its antiviral therapy for rare hepatitis delta virus (HDV) Share XGilead files first hepatitis delta therapy with FDAhttps://pharmaphorum.com/news/gilead-files-first-hepatitis-delta-therapy-with-fda/
NICE reaches a deal with Roche on access to oral SMA drug EvrysdiRoche’s oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on Share XNICE reaches a deal with Roche on access to oral SMA drug Evrysdihttps://pharmaphorum.com/news/nice-reaches-a-deal-with-roche-on-access-to-oral-sma-drug-evrysdi/
NICE backs ViiV/J&J’s six-per-year injection for HIVPeople living with HIV in England and Wales now have an alternative to daily oral tablets, after NICE Share XNICE backs ViiV/J&J’s six-per-year injection for HIVhttps://pharmaphorum.com/news/nice-backs-viiv-jjs-six-per-year-injection-for-hiv/
CHMP minded to turn down Alzheimer’s drug Aduhelm, says BiogenBiogen and Eisai have said that the EMA’s human medicines committee looks unlikely recommended approval of their Alzheimer’s Share XCHMP minded to turn down Alzheimer’s drug Aduhelm, says Biogenhttps://pharmaphorum.com/news/chmp-minded-to-turn-down-alzheimers-drug-aduhelm-says-biogen/
